CD52 and myeloid sarcoma: The absence of CD52 on hematological precursor cells enables maturation and repopulation after treatment, which appears to have a long-lasting tolerance-inducing effect in patients with MS, with more than 50% not requiring disease-modifying therapy 3 years after treatment [11].